This February, the brand continues its See Your Risks initiative by challenging denial and bringing unseen heart health risk factors into view.
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke compared...
‘Highlights REAL’ aims to spark vital conversations about advanced prostate cancer and educate about the importance of treatment management
Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located...
Findings from OCEANIC-STROKE, including the main results and a prespecified subgroup analysis, will be presented for the first time during two late-breaking sessions at the International Stroke Conference...
Not intended for UK Media Collaboration spans across various indications with an initial focus on cardiovascular and kidney diseases, addressing areas of significant...
Bayer is successfully executing on an ambitious growth strategy Five pivotal approvals worldwide in 2025 underscore a landmark year of strategic execution Bayer will...
In the ‘Life Doesn’t Stop for a Hot Flash’ campaign, Gabrielle Union-Wade and Bayer partner together to help raise awareness about an available treatment option for moderate to severe hot flashes...
Not intended for UK Media Bayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance diagnosis...
Not intended for UK Media Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer...